Mnemosyne garners $6M expansion round

Providence, RI-based Mnemosyne Pharmaceuticals says it's added a $6 million expansion round with the help of Atlas Venture and Clal Biotechnology Industries. The startup has two lead programs in schizophrenia and Rett syndrome, with additional work under way on neuropsychiatric disorders like depression. Mnemosyne says it is developing a new class of molecules, Subunit Selective NMDA Receptor Modulators, for the neuropsychiatry market. "The Subunit-selective NMDA Receptor Modulators being developed by Mnemosyne presents an innovative strategy for developing new drugs for neuropsychiatric diseases and we look forward to working with the Mnemosyne team to bring these new candidates to the clinic," said Peter Barrett, a partner at Atlas Venture. Release

Suggested Articles

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.

Grid Therapeutics is planning to start trials of its lead cancer immunotherapy GT103 next year after raising $5 million in second-round financing.

The IPO comes as the Flagship startup prepares to test its lead inflammatory disease and anticancer microbial strains in humans.